Eva Serup-Hansen

Eva Serup-Hansen

Auto-generated profile, based on publicly available information

Eva Serup-Hansen

Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
LÅLina M. Åström
Lina M. Åström
CBClaus P. Behrens
Claus P. Behrens
KSKatrine Smedegaard Storm
Katrine Smedegaard Storm
PSPatrik Sibolt
Patrik Sibolt
ESEva Serup-Hansen
Eva Serup-Hansen
Online adaptive radiotherapy (oART) potentially spares OARs as PTV margins are reduced. This study evaluates dosimetric benefits, compared to standard non-adaptive radiotherapy (non-ART), target propagation methods, and first clinical treatments of CBCT-guided oART of anal cancer. Treatment plans with standard non-ART and reduced oART PTV margins were retrospectively generated for 23 consecutive patients with anal cancer. For five patients randomly selected among the 23 patients, weekly CBCT-guided oART sessions were simulated, where the targets were either deformed or rigidly propagated. Preferred target propagation method and dose to OARs were evaluated. Ten consecutive patients with anal cancer were treated with CBCT-guided oART. Target propagation methods and oART procedure time were evaluated. For the retrospective treatment plans, oART resulted in median reductions in bowel bag V45Gy of 11.4 % and bladder V35Gy of 16.1%. Corresponding values for the simulated sessions were 7.5% and 27.1%. In the simulated sessions, 35% of all targets were deformed while 65% were rigidly propagated. Manual editing and rigid propagation were necessary to obtain acceptable target coverage. In the clinical treatments, the primary and some elective targets were rigidly propagated, while other targets were deformed. The median oART procedure time, measured from CBCT acquisition to completion of plan review and QA, was 23 min. Simulated oART reduced the dose to OARs, indicating potential reduction in toxicity. Rigid propagation of targets was necessary to reduce the need for manual edit. Clinical treatments demonstrated that oART of anal cancer is feasible but time-consuming.

22 May 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
CNCamilla Panduro Nielsen
Camilla Panduro Nielsen
ESEva Samsøe
Eva Samsøe
BOBirgitte Vrou Offersen
Birgitte Vrou Offersen
ELEbbe Laugaard Lorenzen
Ebbe Laugaard Lorenzen
GPGitte F. Persson
Gitte F. Persson
CHChristian Rønn Hansen
Christian Rønn Hansen
Robust quality assurance (QA) of clinical trials in radiotherapy (RT) is paramount for minimising uncertainties in treatment delivery, thereby strengthening the statistical power of the study and increasing the likelihood of accurately answering the research question. As RT techniques evolve and become more complex, establishing an appropriate QA program for a specific clinical trial becomes increasingly challenging, highlighting the importance of clear and standardised recommendations. This study provide such recommendations for Principal Investigators (PIs) to consider when planning and conducting RT Quality Assurance (RTQA) for clinical trials. They arise from experiences with RTQA in the clinical trials conducted in the Danish Multidisciplinary Cancer Groups (DMCGs). The recommendations include a checklist to guide PIs in developing an effective RTQA program.

19 January 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MFMette van Overeem Felter
Mette van Overeem Felter
PMPia Krause Møller
Pia Krause Møller
MJMirjana Josipovic
Mirjana Josipovic
SBSusanne Nørring Bekke
Susanne Nørring Bekke
UBUffe Bernchou
Uffe Bernchou
GPGitte Fredberg Persson
Gitte Fredberg Persson

24 November 2021 in Acta Oncologica
Verified
Journal Article
Closed access
KWKaren Lycke Wind
Karen Lycke Wind
ESEva Serup-Hansen
Eva Serup-Hansen
BHBirgitte Mayland Havelund
Birgitte Mayland Havelund
LRLisbeth Riber
Lisbeth Riber
CKCamilla Jensenius Skovhus Kronborg
Camilla Jensenius Skovhus Kronborg
KSKaren-Lise Spindler
Karen-Lise Spindler
Even though the incidence of squamous cell carcinoma of the anus (SCCA) is rising [1], it is still considered a rare malignancy representing less than 3% of all gastrointestinal cancers [2]. The ma...

27 January 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
MFMette van Overeem Felter
Mette van Overeem Felter
PMPia Krause Møller
Pia Krause Møller
MJMirjana Josipovic
Mirjana Josipovic
SBSusanne Nørring Bekke
Susanne Nørring Bekke
UBUffe Bernchou
Uffe Bernchou
GPGitte Fredberg Persson
Gitte Fredberg Persson
The SOFT (Stereotactic ablative radiotherapy of infra-diaphragmatic sOFT tissue metastases) trial assesses the safety and efficacy of risk-adapted MR-guided stereotactic ablative radiotherapy (SABR) of infra-diaphragmatic soft tissue metastasis in patients with oligometastatic disease (OMD) (clinicaltrials.gov ID NCT04407897). This paper reports the one-year efficacy analysis and evaluates associations between local control (LC) and clinical and dosimetric parameters. This investigator-initiated, multicenter, single-arm, phase 2 study recruited patients from four MR-linac centers in Denmark and the US. Patients with De novo or recurrent OMD with ≤5 metastases in ≤3 organs and patients with induced OMD or oligoprogressive disease (OPD) with ≤3 metastases were eligible. Fractionation schemes were 45-75 Gy in 3-8 fractions. The trial included 121 patients with 147 oligometastatic lesions, primarily in the liver (41 %), lymph nodes (35 %), or adrenal glands (14 %). The median follow-up time was 13.0 months, interquartile range (IQR) (11.7,13.7) months. The 1-year LC rate was 89 %, 95 % confidence interval (CI) (83,94 %). We did not observe any statistically significant associations between LC and clinical and dosimetric parameters. The median progression-free survival was 7.1 months, 95 % CI (6.0,9.4). One- and two-year overall survival was 82.6 %, 95 % CI (76.2 %,89.7 %), and 65.1 %, 95 % CI (56.4 %,75.3 %). Sixty-one patients (50 %) were kept off systemic therapy throughout the one-year follow-up. In our study, treatment with risk-adapted, MR-guided SABR resulted in a high one-year local control and survival rate and could keep half of the patients off systemic therapy within the first year of follow-up.

28 August 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
CKCamilla J S Kronborg
Camilla J S Kronborg
DADennis T Arp
Dennis T Arp
RBRana Bahij
Rana Bahij
SBSusan B N Biancardo
Susan B N Biancardo
LDLaura V Diness
Laura V Diness
HNHenrik D Nissen
Henrik D Nissen
Background and purpose: Sexual dysfunction is a common consequence of pelvic radiotherapy, influenced by psychological, physical, social, and relational factors. Research has focused on vaginal dose and stenosis in females and penile bulb dose and erectile dysfunction in males, with limited attention to domains, such as arousal, desire, and satisfaction. In the Danish Colorectal Cancer Radiotherapy Group, we aimed to: (1) Develop an atlas of sexual function-related organs at risk and (2) Evaluate if these organs at risk could be spared without compromising target coverage in rectal cancer radiotherapy planning. Patient/material and methods: A multidisciplinary approach was adopted, involving oncology, physics, psychology, surgery, and radiology. MRI-based anatomical definitions were established, and an atlas was created for both males and females, including inferior hypogastric plexus, pudendal vessels/Alcock’s canal, neurovascular bundle, penile bulb, vagina, paracolpium, and bulboclitoris. For comparative planning standard and sexual function-sparing plans were created for each patient. Results: A national consensus atlas for sexual function-related organs at risk was developed. Standard plans (n = 15) and sexual function-sparing plans (n = 15) for seven males and eight females were compared. Sparing of pudendal vessels and bulboclitoris was feasible without compromising the standard plan. For sexual function-related organs at risk in or close to the target, D2% could often be improved. Interpretation: Our consensus-based delineation and planning demonstrate that radiation dose to many sexual function-related organs at risk can be spared or optimized without compromising target coverage or dose to standard organs at risk. Future work includes implementing patient-reported outcomes and integrating these new organs at risk into standard radiotherapy planning.